市場調査レポート
商品コード
1491992

自己幹細胞/非幹細胞治療の世界市場:タイプ別、適応症別、由来別、エンドユーザー別 - 予測(~2029年)

Autologous Stem Cell & Non-stem Cell Therapies Market by Type (CAR-T, Tumor Infiltrating Lymphocyte), Indication (Cancer, Musculoskeletal, Dermatology), Source (T-Cells, Mesenchymal Stem Cell), End User (Hospital) - Global Forecast to 2029

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 295 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
自己幹細胞/非幹細胞治療の世界市場:タイプ別、適応症別、由来別、エンドユーザー別 - 予測(~2029年)
出版日: 2024年06月07日
発行: MarketsandMarkets
ページ情報: 英文 295 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の自己幹細胞/非幹細胞治療の市場規模は、2024年の55億米ドルから2029年までに222億米ドルに達すると予測され、予測期間にCAGRで32.3%の成長が見込まれます。

市場の成長は、自己CAR-T細胞ベースの治療に対する規制当局の承認の増加、自己細胞治療の開発に向けた研究開発投資の増加、個別化医療に対する需要の増加などの要因によって促進されています。

調査範囲
調査対象年 2022年~2029年
基準年 2023年
予測期間 2024年~2029年
単位 金額(100万米ドル)
セグメント タイプ別、適応症別、由来別、エンドユーザー別、地域別
対象地域 北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ

「自己幹細胞/非幹細胞治療市場の成長は、がん患者が増加し、多くの治療オプションに対する需要が増加していることによるものと考えられます。」

自己非幹細胞治療が支配的なシェアを占めているのは、世界のがん患者の増加により、自己非幹細胞治療などの効果的ながん治療ソリューションの開発に対する需要が加速しているためであり、これらの治療に対する規制当局の承認件数の増加や、実行可能な治療オプションを求めるがん患者の増加により、市場での評価が高まっています。

「適応症別では、がん適応症サブセグメントが2023年に市場で最大のシェアを占めました。」

2023年、がん適応症サブセグメントが適応症セグメントで最大のシェアを占めました。これは、世界のがん患者数の増加や、自己CAR-T細胞治療などの効果的かつ効率的ながん治療の開発に対する需要の高まりによるものであり、自己CAR-T細胞治療は多発性骨髄腫や各種リンパ腫などのさまざまな形態のがんの治療に有効であることが示されています。

「北米が市場でもっとも高いCAGRを記録すると予測されます。」

北米の医療部門の拡大や、がんなどの慢性疾患に対する自己幹細胞/非幹細胞治療の承認と利用の高まりに加え、自己幹細胞/非幹細胞を用いた研究に対する学術的および組織的な関心の高まりが、北米の市場成長の促進要因となっています。さらに、北米の確立された製薬インフラや、Gilead Sciences, Inc.(米国)、Bristol-Myers Squibb Company(米国)、Johnson & Johnson(米国)などの市場の有力企業のプレゼンスも、この地域の主導的地位を支えています。

当レポートでは、世界の自己幹細胞/非幹細胞治療市場について調査分析し、主な促進要因と抑制要因、競合情勢、将来の動向などの情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 自己幹細胞/非幹細胞治療市場の概要
  • 北米の自己幹細胞/非幹細胞治療市場:タイプ別、国別(2023年)
  • 自己幹細胞/非幹細胞治療の市場シェア:由来別(2024年対2029年)
  • 自己幹細胞/非幹細胞治療の市場シェア:適応症別(2023年)
  • 自己幹細胞/非幹細胞治療市場:地理的成長機会

第5章 市場の概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • サプライチェーン分析
  • 技術分析
    • 主要技術
    • 補完技術
  • バリューチェーン分析
  • 価格分析
  • エコシステム分析
  • 顧客のビジネスに影響を与える動向/混乱
  • 特許分析
    • 特許分析:自己CAR-T治療
    • 特許分析:TIL治療
  • 主な会議とイベント(2024年~2025年)
  • 規制情勢
    • 規制分析
    • 北米
    • 欧州
    • アジア太平洋
    • 規制機関と組織
  • ポーターのファイブフォース分析
  • 主なステークホルダーと購入基準
  • 主な購入基準
    • 自己幹細胞/非幹細胞治療製品に対するエンドユーザーの購入基準
    • 自己幹細胞/非幹細胞治療製品の購入基準:エンドユーザー別
  • 投資と資金調達のシナリオ
  • ケーススタディ分析

第6章 自己幹細胞/非幹細胞治療市場:タイプ別

  • イントロダクション
  • 自己幹細胞治療
  • 自己非幹細胞治療
  • CAR-T細胞治療
  • 腫瘍浸潤リンパ球(TIL)

第7章 自己幹細胞/非幹細胞治療市場:適応症別

  • イントロダクション
  • がん適応症
  • 筋骨格適応症
  • 皮膚科適応症
  • その他の適応症

第8章 自己幹細胞/非幹細胞治療市場:由来別

  • イントロダクション
  • T細胞
  • 間葉系幹細胞

第9章 自己幹細胞/非幹細胞治療市場:エンドユーザー別

  • イントロダクション
  • 病院、診療所
  • 長期ケア施設
  • 専門ケアセンター

第10章 自己幹細胞/非幹細胞治療市場:地域別

  • イントロダクション
  • 北米
    • 北米に対する不況の影響
    • 米国
    • カナダ
  • 欧州
    • 欧州に対する不況の影響
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • アジア太平洋に対する不況の影響
    • 日本
    • 中国
    • インド
    • 韓国
    • その他のアジア太平洋
  • ラテンアメリカ
    • ラテンアメリカに対する不況の影響
    • ブラジル
    • メキシコ
    • アルゼンチン
    • その他のラテンアメリカ
  • 中東
    • 中東に対する不況の影響
    • GCC諸国
  • アフリカ

第11章 競合情勢

  • 概要
  • 主な企業戦略/有力企業
  • 収益分析
  • 市場シェア分析
  • 企業評価マトリクス:主要企業(2023年)
  • 企業評価マトリクス:スタートアップ/中小企業(2023年)
  • 企業評価と財務指標
  • ブランド/製品の比較
    • GILEAD SCIENCES, INC.
    • BRISTOL-MYERS SQUIBB COMPANY
    • NOVARTIS AG
  • 競合シナリオ

第12章 企業プロファイル

  • 主要企業
    • BRISTOL-MYERS SQUIBB COMPANY
    • GILEAD SCIENCES, INC.
    • NOVARTIS AG
    • JOHNSON & JOHNSON
    • VERICEL CORPORATION
    • IOVANCE BIOTHERAPEUTICS, INC.
    • JW (CAYMAN) THERAPEUTICS CO. LTD
    • PHARMICELL CO., LTD.
    • HOLOSTEM S.R.L.
    • HEALIVA SA
    • APAC BIOTECH
    • IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT)
    • REGROW BIOSCIENCES PVT LTD.
    • TEGO SCIENCE, INC.
    • CARSGEN THERAPEUTICS HOLDINGS LIMITED
    • IASO BIOTHERAPEUTICS
    • ANTEROGEN.CO., LTD.
    • GREEN CROSS HOLDINGS CO., LTD. (GC CELL)
    • SANPOWER GROUP CO., LTD. (DENDREON PHARMACEUTICALS LLC.)
  • その他の企業
    • PROKIDNEY CORP.
    • BIOCARDIA, INC.
    • NEUROPLAST B.V.
    • ADAPTIMMUNE THERAPEUTICS PLC
    • AGONOX, INC.
    • KYVERNA THERAPEUTICS, INC.
    • OBSIDIAN THERAPEUTICS, INC.
    • AVOTRES INC.
    • CORESTEMCHEMON INC.
    • JUVENTAS CELL THERAPY LTD.

第13章 付録

目次
Product Code: PH 1300

The autologous stem cell & non-stem cell therapies market is projected to reach USD 22.2 billion by 2029 from USD 5.5 billion in 2024, at a CAGR of 32.3% during the forecast period. The growth of this market is driven by several factors such as the growing regulatory approvals for autologous CAR T cell-based therapies, increasing R&D investments for the development of autologous cell therapies, and an increase in the demand for personalized medicines.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD) Million
SegmentsBy Type, Indication, Source, End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

"The autologous stem cell & non-stem cell therapies market growth for Autologous non-stem cell therapies can be attributed to the increasing number of cancer cases leading to increased demand for substantial treatment option."

The autologous stem cell & non-stem cell therapies market, based on type segment is further segmented into autologous stem cell therapies and autologous non-stem cell therapies. The autologous non-stem cell therapies sub-segment is further divided into CAR T cell therapies, Tumor Infiltrating Lymphocyte (TIL), and other therapies (of skin grafts, others). The autologous non-stem cell therapies hold the dominant share due to the rise in global cancer cases accelerating the demand for the development of effective cancer treatment solutions such as autologous non-stem-cell-based therapies, which are increasingly valued in the market due to the rising number of regulatory approvals for these therapies and growing number of cancer patients seeking viable treatment alternatives.

"By Indications, the cancer indication subsegment accounted for the largest share of the autologous stem cell & non-stem cell therapies market in 2023."

The indication segment is further segmented into cancer indications and non-cancer indications. In 2023, the cancer indications subsegment accounted for the largest share of the indication segment due to the rising number of global cancer cases, and a growing demand for the development of effective and efficient cancer therapeutics such as autologous CAR T cell therapies, that are shown to be effective for treating various forms of cancer such as multiple myeloma and various types of lymphoma.

"North American region is expected to register the highest CAGR in the autologous stem cell & non-stem cell therapies market."

The market for autologous stem cell & non-stem cell therapies in North America is estimated to grow at the highest rate during the forecast period. The rising academic and organizational interest in autologous stem cell and non-stem cell-based research, complemented by the North American healthcare sector's expansion and the rising approvals and utilization of autologous stem cell and non-stem cell-based therapies for cancer and other chronic diseases are factors that will aid the market growth in North America. North America also has an established pharmaceutical manufacturing infrastructure and the presence of prominent players in the autologous stem cell & non-stem cell therapies market such as Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US) among others which further supports the leadership position of this region.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side - 30%
  • By Designation: C Level Executives- 55%, CXOs, and Director level - 20%, and Others- 25%
  • By Region: North America -50%, Europe - 20%, Asia-Pacific -20%, RoW -10%

List of Companies Profiled in the Report

  • Gilead Sciences, Inc. (US)
  • Bristol-Myers Squibb Company (US)
  • Johnson & Johnson (US)
  • Vericel Corporation (US)
  • Novartis AG (Switzerland)
  • JW (Cayman) Therapeutics Co. Ltd (China)
  • APAC Biotech (India)
  • Regrow Biosciences Pvt Ltd. (India)
  • Healiva SA (Switzerland)

Note: The above list is inexhaustive

Research Coverage:

This report provides a detailed picture of the autologous stem cell & non-stem cell therapies market. It aims to estimate the market's size and future growth potential across different segments such as the type, indication, source, end user, and region. The report also includes an in-depth competitive analysis of the key market players and their company profiles, recent developments, key market strategies, funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the autologous stem cell & non-stem cell therapies market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall autologous stem cell & non-stem cell therapies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (e.g., increasing government approvals for various autologous cell-based therapies, increasing investments and funding towards the development of autologous cell-based therapies and the growing number of clinical trials involving autologous stem and non-stem cells), restraints (e.g., uptake of allogeneic cell-based therapies as substitutes), opportunities (e.g, outsourcing manufacturing of cell therapy and focus on closed automated systems), and challenges (e.g, regulatory complications and reimbursement challenges and issues in scalable manufacturing) are influencing the growth of the autologous stem cell & non-stem cell therapies market.
  • Product Approvals: Detailed insights on newly approved products of the autologous stem cell & non-stem cell therapies market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the autologous stem cell & non-stem cell therapies market across varied regions.
  • Market Diversification: Exhaustive information about new products, recent developments, and investments in the autologous stem cell & non-stem cell therapies market.
  • Pipeline Analysis: Comprehensive information about products under clinical trials.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players including Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), Vericel Corporation (US), Novartis AG (Switzerland), JW (Cayman) Therapeutics Co. Ltd (China), Iovance Biotherapeutics, Inc. (US), APAC Biotech (India), Regrow Biosciences Pvt Ltd. (India), healiva SA (Switzerland), Green Cross Holdings Co., Ltd. (GC Cell) (Republic of Korea)), Sanpower Group Co., Ltd. (Dendreon Pharmaceuticals Llc. (China), Tegoscience (South Korea), ImmunoACT (India), CARsgen Therapeutics Holdings Limited (China), IASO Biotherapeutics (China), Pharmicell Co., Ltd (South Korea), Anterogen.Co.,Ltd. (South Korea) among others offering autologous stem cell & non-stem cell-based therapeutic products.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKET SEGMENTATION
    • 1.3.2 REGIONAL SEGMENTATION
    • FIGURE 1 REGIONS COVERED
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES
  • 1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 BREAKDOWN OF PRIMARIES: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS, 2023
    • FIGURE 5 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: REVENUE SHARE ANALYSIS, 2023
    • FIGURE 6 GILEAD SCIENCES, INC.: REVENUE SHARE ANALYSIS, 2023
  • 2.3 PRIMARY INSIGHTS
    • FIGURE 7 VALIDATION FROM PRIMARY EXPERTS
    • 2.3.1 SEGMENTAL ASSESSMENT
    • FIGURE 8 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • 2.4 GROWTH FORECAST
    • FIGURE 9 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: CAGR PROJECTIONS (2024-2029)
    • FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 2.5 VOLUME ESTIMATION
  • 2.6 MARKET BREAKDOWN & DATA TRIANGULATION
    • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • 2.7 STUDY ASSUMPTIONS
  • 2.8 RISK ANALYSIS
    • TABLE 1 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: RISK ASSESSMENT ANALYSIS
  • 2.9 RECESSION IMPACT ANALYSIS
    • TABLE 2 GLOBAL INFLATION RATE PROJECTIONS, 2021-2028 (% GROWTH)

3 EXECUTIVE SUMMARY

    • FIGURE 12 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 13 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION)
    • FIGURE 14 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 15 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2024-2029
    • FIGURE 16 GEOGRAPHICAL SNAPSHOT OF AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET

4 PREMIUM INSIGHTS

  • 4.1 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET OVERVIEW
    • FIGURE 17 RISING REGULATORY APPROVALS FOR CAR T-CELL THERAPIES TO DRIVE MARKET
  • 4.2 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE AND COUNTRY (2023)
    • FIGURE 18 AUTOLOGOUS NON-STEM CELL THERAPIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • 4.3 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SHARE, BY SOURCE, 2024 VS. 2029
    • FIGURE 19 T-CELLS SOURCE SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.4 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SHARE, BY INDICATION, 2023
    • FIGURE 20 CANCER INDICATION SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
  • 4.5 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 21 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 22 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 3 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising approvals for CAR T-cell therapies
    • TABLE 4 APPROVED AUTOLOGOUS CAR T-CELL THERAPIES
      • 5.2.1.2 Increasing R&D investments in autologous therapeutics
      • 5.2.1.3 Increasing demand for personalized medicine
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Uptake of allogeneic cell-based therapies as substitutes
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising outsourcing of manufacturing activities
      • 5.2.3.2 Adoption of closed automated systems
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Stringent regulatory guidelines and reimbursement challenges
      • 5.2.4.2 Issues associated with scalable manufacturing
  • 5.3 SUPPLY CHAIN ANALYSIS
    • FIGURE 23 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
  • 5.4 TECHNOLOGY ANALYSIS
    • 5.4.1 KEY TECHNOLOGIES
      • 5.4.1.1 Genome editing
      • 5.4.1.2 Synthetic biology
    • 5.4.2 COMPLEMENTARY TECHNOLOGIES
      • 5.4.2.1 Process analytical technology (PAT)
      • 5.4.2.2 Point-of-care manufacturing
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 24 VALUE CHAIN ANALYSIS-MAXIMUM VALUE IS ADDED DURING THERAPY MANUFACTURING PHASE
  • 5.6 PRICING ANALYSIS
    • TABLE 5 AVERAGE SELLING PRICE FOR LEADING AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPEUTIC DRUGS
    • TABLE 6 AVERAGE SELLING PRICE FOR MAJOR AUTOLOGOUS STEM CELL AND NON-STEM CELL BASED THERAPEUTIC DRUGS, BY REGION
  • 5.7 ECOSYSTEM ANALYSIS
    • 5.7.1 ROLE IN ECOSYSTEM
  • 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 26 REVENUE SHIFT AND NEW REVENUE POCKETS FOR AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPY MARKET MANUFACTURERS
  • 5.9 PATENT ANALYSIS
    • 5.9.1 PATENT ANALYSIS: AUTOLOGOUS CAR-T THERAPIES
    • FIGURE 27 PATENT APPLICATIONS FOR AUTOLOGOUS CAR-T THERAPIES, JANUARY 2013-OCTOBER 2023
    • 5.9.2 PATENT ANALYSIS: TIL THERAPY
    • FIGURE 28 PATENT APPLICATIONS FOR TIL THERAPIES, JANUARY 2013-OCTOBER 2023
  • 5.10 KEY CONFERENCES & EVENTS, 2024-2025
    • TABLE 7 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: LIST OF CONFERENCES & EVENTS
  • 5.11 REGULATORY LANDSCAPE
    • 5.11.1 REGULATORY ANALYSIS
    • 5.11.2 NORTH AMERICA
      • 5.11.2.1 US
      • 5.11.2.2 Canada
    • 5.11.3 EUROPE
      • 5.11.3.1 Germany
      • 5.11.3.2 UK
      • 5.11.3.3 Rest of Europe
    • 5.11.4 ASIA PACIFIC
      • 5.11.4.1 China
      • 5.11.4.2 Japan
      • 5.11.4.3 South Korea
      • 5.11.4.4 Australia
      • 5.11.4.5 Rest of Asia Pacific
    • 5.11.5 REGULATORY BODIES AND ORGANIZATIONS
    • TABLE 8 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.12 PORTER'S FIVE FORCES ANALYSIS
    • FIGURE 29 AUTOLOGOUS STEM CELL & NON-STEM CELL MARKET: PORTER'S FIVE FORCE ANALYSIS
    • TABLE 13 PORTER'S FIVE FORCES ANALYSIS
    • 5.12.1 DEGREE OF COMPETITION
    • 5.12.2 BARGAINING POWER OF SUPPLIERS
    • 5.12.3 BARGAINING POWER OF BUYERS
    • 5.12.4 THREAT OF SUBSTITUTES
    • 5.12.5 THREAT OF NEW ENTRANTS
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    • FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
  • 5.14 KEY BUYING CRITERIA
    • 5.14.1 BUYING CRITERIA OF END USERS FOR AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPEUTIC PRODUCTS
    • 5.14.2 BUYING CRITERIA FOR AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPEUTIC PRODUCTS, BY END USER
  • 5.15 INVESTMENT AND FUNDING SCENARIO
  • 5.16 CASE STUDY ANALYSIS
    • 5.16.1 CASE STUDY 1
      • 5.16.1.1 Comparative Analysis of Cupistem Efficacy in Treatment of Crohn's Perianal Fistulas
    • 5.16.2 CASE STUDY 2
      • 5.16.2.1 Evaluating Lenzumestrocel (Neuronata-R) in Amyotrophic Lateral Sclerosis: The ALSUMMIT Phase III Trial Protocol
    • 5.16.3 CASE STUDY 3
      • 5.16.3.1 Stemirac Stem Cell Therapy for Traumatic Spinal Cord Injury
    • 5.16.4 CASE STUDY 4
      • 5.16.4.1 Efficacy and Safety of Holoclar in Limbal Stem Cell Deficiency

6 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 14 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 15 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (UNITS)
  • 6.2 AUTOLOGOUS STEM CELL THERAPIES
    • 6.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET
    • TABLE 16 AUTOLOGOUS STEM CELL THERAPIES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 17 NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 18 EUROPE: AUTOLOGOUS STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 19 ASIA PACIFIC: AUTOLOGOUS STEM CELL MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 20 LATIN AMERICA: AUTOLOGOUS STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 21 MIDDLE EAST: AUTOLOGOUS STEM CELL MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 22 GCC COUNTRIES: AUTOLOGOUS STEM CELL MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.3 AUTOLOGOUS NON-STEM CELL THERAPIES
    • TABLE 23 AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 24 AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 25 NORTH AMERICA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 26 EUROPE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 27 ASIA PACIFIC: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.4 CAR T-CELL THERAPIES
    • 6.4.1 GROWING APPROVAL OF AUTOLOGOUS CAR T-CELL THERAPIES TO BOOST GROWTH
    • TABLE 28 CAR T-CELL THERAPIES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 29 NORTH AMERICA: CAR T-CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 30 EUROPE: CAR T-CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 31 ASIA PACIFIC: CAR T-CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • 6.5 TUMOR-INFILTRATING LYMPHOCYTES (TILS)
    • 6.5.1 EMERGING POTENTIAL OF TIL IN CANCER TREATMENT TO BOOST DEMAND
    • TABLE 32 TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 33 NORTH AMERICA: TUMOR-INFILTRATING LYMPHOCYTES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)

7 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION

  • 7.1 INTRODUCTION
    • TABLE 34 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
  • 7.2 CANCER INDICATION
    • 7.2.1 RISING INCIDENCE OF CANCER AND GROWING DEMAND FOR THERAPEUTICS TO DRIVE MARKET
    • TABLE 35 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKEY FOR CANCER INDICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 36 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR CANCER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 37 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR CANCER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 38 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR CANCER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.3 MUSCULOSKELETAL INDICATION
    • 7.3.1 GROWING INCIDENCE OF OSTEOARTHRITIS TO DRIVE MARKET
    • TABLE 39 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 40 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 41 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 42 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 43 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 44 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 45 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MUSCULOSKELETAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.4 DERMATOLOGY INDICATION
    • 7.4.1 INCREASING PREVALENCE OF SKIN DISORDERS TO SUPPORT MARKET GROWTH
    • TABLE 46 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 47 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 48 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 49 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 50 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 51 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 52 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR DERMATOLOGICAL INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 7.5 OTHER INDICATIONS
    • TABLE 53 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 54 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 55 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 56 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 57 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 58 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 59 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)

8 AUTOLOGOUS STEM CELL AND NON-STEM CELL THERAPIES MARKET, BY SOURCE

  • 8.1 INTRODUCTION
    • TABLE 60 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • 8.2 T-CELLS
    • 8.2.1 GROWING ADOPTION OF CAR T-CELL THERAPIES TO DRIVE MARKET
    • TABLE 61 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 62 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 63 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 64 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR T-CELLS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 8.3 MESENCHYMAL STEM CELLS
    • 8.3.1 HIGH UPTAKE IN DEVELOPMENT OF AUTOLOGOUS THERAPIES TO SUPPORT MARKET GROWTH
    • TABLE 65 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 66 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 67 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 68 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 69 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 70 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 71 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR MESENCHYMAL STEM CELLS, BY COUNTRY, 2022-2029 (USD MILLION)

9 AUTOLOGOUS STEM-CELL & NON-STEM CELL THERAPIES MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 72 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 9.2 HOSPITALS AND CLINICS
    • 9.2.1 ABILITY TO UNDERTAKE APHERESIS PROCEDURES WITH ADVANCED HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET
    • TABLE 73 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 74 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 75 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 76 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 77 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 78 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 79 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • 9.3 LONG-TERM CARE FACILITIES
    • 9.3.1 RISING INCIDENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH
    • TABLE 80 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 81 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 82 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 83 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 84 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 85 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 86 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • 9.4 SPECIALTY CARE CENTERS
    • 9.4.1 GROWING PREFERENCE FOR PERSONALIZED MEDICINE TO BOOST DEMAND
    • TABLE 87 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 88 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 89 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 90 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 91 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 92 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 93 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR SPECIALTY CARE CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)

10 AUTOLOGOUS STEM CELL AND NON-STEM STEM CELL THERAPIES MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 94 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 10.2 NORTH AMERICA
    • 10.2.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 31 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SNAPSHOT
    • TABLE 95 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 96 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 97 NORTH AMERICA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 98 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 99 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 100 NORTH AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.2.2 US
      • 10.2.2.1 Rising R&D activities for stem cell therapies to drive market
    • TABLE 101 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 102 US: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 103 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 104 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 105 US: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Rising government initiatives for regenerative medicine research to drive market
    • TABLE 106 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 107 CANADA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 108 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 109 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 110 CANADA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 10.3 EUROPE
    • 10.3.1 EUROPE: RECESSION IMPACT
    • TABLE 111 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 112 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 113 EUROPE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 114 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 115 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 116 EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.3.2 GERMANY
      • 10.3.2.1 Rising focus on clinical research to drive market
    • TABLE 117 GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 118 GERMANY: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 119 GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 120 GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 121 GERMANY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.3.3 UK
      • 10.3.3.1 Rising technological advancements in automation to drive market
    • TABLE 122 UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 123 UK: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 124 UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 125 UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 126 UK: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.3.4 FRANCE
      • 10.3.4.1 Growing focus on cell & gene therapy initiatives to boost demand
    • TABLE 127 FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 128 FRANCE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 129 FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 130 FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 131 FRANCE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.3.5 ITALY
      • 10.3.5.1 Growth in biotech sector to drive market
    • TABLE 132 ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 133 ITALY: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 134 ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 135 ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 136 ITALY: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.3.6 SPAIN
      • 10.3.6.1 Rising focus on stem cell banking to support market growth
    • TABLE 137 SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 138 SPAIN: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 139 SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 140 SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 141 SPAIN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 142 REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 143 REST OF EUROPE: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 144 REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 145 REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 146 REST OF EUROPE: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • 10.4.1 ASIA PACIFIC: RECESSION IMPACT
    • FIGURE 32 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SNAPSHOT
    • TABLE 147 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 148 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 149 ASIA PACIFIC: AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 150 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 151 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 152 ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Increasing product approvals to drive market
    • TABLE 153 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 154 JAPAN: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 155 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 156 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 157 JAPAN: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.4.3 CHINA
      • 10.4.3.1 Rising number of CAR T-cell clinical trials to support market growth
    • TABLE 158 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 159 CHINA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 160 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 161 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 162 CHINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Rising incidence of cancer and growing focus on product commercialization to boost demand
    • TABLE 163 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 164 INDIA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 165 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 166 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 167 INDIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.4.5 SOUTH KOREA
      • 10.4.5.1 Rising growth in biopharmaceutical industry to drive market
    • TABLE 168 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 169 SOUTH KOREA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 170 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 171 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 172 SOUTH KOREA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.4.6 REST OF ASIA PACIFIC
    • TABLE 173 REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 174 REST OF ASIA PACIFIC: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 175 REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 176 REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 177 REST OF ASIA PACIFIC: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 LATIN AMERICA: RECESSION IMPACT
    • TABLE 178 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 179 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 180 LATIN AMERICA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 181 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 182 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 183 LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.5.2 BRAZIL
      • 10.5.2.1 High expenditure on healthcare to support market growth
    • TABLE 184 BRAZIL: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 185 BRAZIL: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 186 BRAZIL: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 187 BRAZIL: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 188 BRAZIL: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.5.3 MEXICO
      • 10.5.3.1 Low operating costs to support market growth
    • TABLE 189 MEXICO: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 190 MEXICO: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 191 MEXICO: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 192 MEXICO: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 193 MEXICO: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.5.4 ARGENTINA
      • 10.5.4.1 Funding for stem cell research to drive market
    • TABLE 194 ARGENTINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 195 ARGENTINA: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 196 ARGENTINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 197 ARGENTINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 198 ARGENTINA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.5.5 REST OF LATIN AMERICA
    • TABLE 199 REST OF LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 200 REST OF LATIN AMERICA: AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 201 REST OF LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 202 REST OF LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 203 REST OF LATIN AMERICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 10.6 MIDDLE EAST
    • 10.6.1 MIDDLE EAST: RECESSION IMPACT
    • TABLE 204 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 205 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 206 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 207 MIDDLE EAST: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 208 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 209 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 210 MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.6.2 GCC COUNTRIES
    • TABLE 211 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 212 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 213 GCC COUNTRIES: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 214 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 215 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 216 GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
      • 10.6.2.1 Kingdom of Saudi Arabia (KSA)
        • 10.6.2.1.1 Growing demand for novel therapeutics to boost demand
    • TABLE 217 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 218 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 219 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 220 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 221 KINGDOM OF SAUDI ARABIA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
      • 10.6.2.2 United Arab Emirates (UAE)
        • 10.6.2.2.1 Growing focus on automation of platforms to fuel market
    • TABLE 222 UNITED ARAB EMIRATES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 223 UNITED ARAB EMIRATES: AUTOLOGOUS NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 224 UNITED ARAB EMIRATES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 225 UNITED ARAB EMIRATES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 226 UNITED ARAB EMIRATES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
      • 10.6.2.3 Other GCC Countries
    • TABLE 227 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 228 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 229 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 230 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 231 OTHER GCC COUNTRIES: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
      • 10.6.2.4 Rest of the Middle East
    • TABLE 232 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 233 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 234 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 235 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 236 REST OF MIDDLE EAST: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 10.7 AFRICA
    • 10.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
    • TABLE 237 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 238 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET FOR AUTOLOGOUS NON-STEM CELL THERAPIES, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 239 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE, 2022-2029 (USD MILLION)
    • TABLE 240 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION, 2022-2029 (USD MILLION)
    • TABLE 241 AFRICA: AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 10.7.2 AFRICA: RECESSION IMPACT

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • FIGURE 33 STRATEGIES ADOPTED BY KEY PLAYERS
  • 11.3 REVENUE ANALYSIS
    • FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS, 2021-2023
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 35 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES: MARKET SHARE ANALYSIS, 2023 (TOP 3 PLAYERS)
    • TABLE 242 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: DEGREE OF COMPETITION
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 36 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 11.5.5.1 Company footprint
    • FIGURE 37 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: COMPANY FOOTPRINT
      • 11.5.5.2 Region footprint
    • TABLE 243 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: REGION FOOTPRINT
      • 11.5.5.3 Type footprint
    • TABLE 244 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: TYPE FOOTPRINT
      • 11.5.5.4 Source footprint
    • TABLE 245 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: SOURCE FOOTPRINT
      • 11.5.5.5 Indication footprint
    • TABLE 246 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: INDICATION FOOTPRINT
  • 11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 STARTING BLOCKS
    • FIGURE 38 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
    • 11.6.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2023
    • TABLE 247 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: DETAILED LIST OF KEY START-UPS/SMES
    • FIGURE 39 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: OVERALL FOOTPRINT FOR START-UPS/SMES
    • TABLE 248 AUTOLOGOUS STEM-CELL & NON-STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
  • 11.7 COMPANY VALUATION & FINANCIAL METRICS
    • FIGURE 40 EV/EBITDA OF KEY VENDORS
    • FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • 11.8 BRAND/PRODUCT COMPARISON
    • TABLE 249 BRAND/PRODUCT COMPARISON FOR AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES (APPROVED THERAPIES)
    • 11.8.1 GILEAD SCIENCES, INC.
    • 11.8.2 BRISTOL-MYERS SQUIBB COMPANY
    • 11.8.3 NOVARTIS AG
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 250 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2024
    • 11.9.2 DEALS
    • TABLE 251 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: DEALS, JANUARY 2021-MAY 2024
    • TABLE 252 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET: EXPANSIONS, JANUARY 2021-MAY 2024
    • 11.9.3 OTHER DEVELOPMENTS
    • TABLE 253 AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPY MARKET: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2024

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 BRISTOL-MYERS SQUIBB COMPANY
    • TABLE 254 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
    • FIGURE 42 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2023)
    • TABLE 255 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED
    • TABLE 256 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS, JANUARY 2021-MAY 2024
    • TABLE 257 BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2021- MAY 2024
    • 12.1.2 GILEAD SCIENCES, INC.
    • TABLE 258 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
    • FIGURE 43 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 259 GILEAD SCIENCES, INC.: PRODUCTS OFFERED
    • TABLE 260 GILEAD SCIENCES, INC.: PRODUCT APPROVALS, JANUARY 2021-MAY 2024
    • TABLE 261 GILEAD SCIENCES, INC.: DEALS, JANUARY 2021-MAY 2024
    • TABLE 262 GILEAD SCIENCES, INC.: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2024
    • 12.1.3 NOVARTIS AG
    • TABLE 263 NOVARTIS AG: COMPANY OVERVIEW
    • FIGURE 44 NOVARTIS AG: COMPANY SNAPSHOT
    • TABLE 264 NOVARTIS AG: PRODUCTS OFFERED
    • TABLE 265 NOVARTIS AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2024
    • TABLE 266 NOVARTIS AG: EXPANSIONS, JANUARY 2021-MAY 2024
    • TABLE 267 NOVARTIS AG: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2024
    • 12.1.4 JOHNSON & JOHNSON
    • TABLE 268 JOHNSON & JOHNSON: COMPANY OVERVIEW
    • FIGURE 45 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2023)
    • TABLE 269 JOHNSON & JOHNSON: PRODUCTS OFFERED
    • TABLE 270 JOHNSON & JOHNSON: PRODUCT APPROVALS, JANUARY 2021-MAY 2024
    • TABLE 271 JOHNSON & JOHNSON: DEALS, JANUARY 2021-MAY 2024
    • 12.1.5 VERICEL CORPORATION
    • TABLE 272 VERICEL CORPORATION: COMPANY OVERVIEW
    • FIGURE 46 VERICEL CORPORATION: COMPANY SNAPSHOT (2023)
    • TABLE 273 VERICEL CORPORATION: PRODUCTS OFFERED
    • TABLE 274 VERICEL CORPORATION: EXPANSIONS, JANUARY 2021-MAY 2024
    • 12.1.6 IOVANCE BIOTHERAPEUTICS, INC.
    • TABLE 275 IOVANCE BIOTHERAPEUTICS, INC.: COMPANY OVERVIEW
    • FIGURE 47 IOVANCE BIOTHERAPEUTICS, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 276 IOVANCE BIOTHERAPEUTICS, INC.: PRODUCTS OFFERED
    • TABLE 277 IOVANCE BIOTHERAPEUTICS, INC.: PRODUCT APPROVALS, JANUARY 2021-MAY 2024
    • TABLE 278 IOVANCE BIOTHERAPEUTICS, INC.: EXPANSIONS, JANUARY 2021-MAY 2024
    • 12.1.7 JW (CAYMAN) THERAPEUTICS CO. LTD
    • TABLE 279 JW (CAYMAN) THERAPEUTICS CO. LTD: COMPANY OVERVIEW
    • FIGURE 48 JW (CAYMAN) THERAPEUTICS CO. LTD: COMPANY SNAPSHOT (2023)
    • TABLE 280 JW (CAYMAN) THERAPEUTICS CO. LTD: PRODUCTS OFFERED
    • TABLE 281 JW (CAYMAN) THERAPEUTICS CO. LTD: PRODUCT APPROVALS, JANUARY 2021-MAY 2024
    • TABLE 282 JW (CAYMAN) THERAPEUTICS CO. LTD: DEALS
    • 12.1.8 PHARMICELL CO., LTD.
    • TABLE 283 PHARMICELL CO., LTD.: COMPANY OVERVIEW
    • TABLE 284 PHARMICELL CO., LTD: PRODUCTS OFFERED
    • 12.1.9 HOLOSTEM S.R.L.
    • TABLE 285 HOLOSTEM S.R.L.: COMPANY OVERVIEW
    • TABLE 286 HOLOSTEM SRL: PRODUCTS OFFERED
    • 12.1.10 HEALIVA SA
    • TABLE 287 HEALIVA SA: COMPANY OVERVIEW
    • TABLE 288 HEALIVA SA: PRODUCTS OFFERED
    • TABLE 289 HEALIVA SA: DEALS
    • 12.1.11 APAC BIOTECH
    • TABLE 290 APAC BIOTECH: COMPANY OVERVIEW
    • TABLE 291 APAC BIOTECH: PRODUCTS OFFERED
    • 12.1.12 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED (IMMUNOACT)
    • TABLE 292 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: COMPANY OVERVIEW
    • TABLE 293 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: PRODUCTS OFFERED
    • TABLE 294 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: DEALS
    • TABLE 295 IMMUNOADOPTIVE CELL THERAPY PRIVATE LIMITED: OTHER DEVELOPMENTS, JANUARY 2021-MAY 2024
    • 12.1.13 REGROW BIOSCIENCES PVT LTD.
    • TABLE 296 REGROW BIOSCIENCES PVT LTD.: COMPANY OVERVIEW
    • TABLE 297 REGROW BIOSCIENCES PVT LTD.: PRODUCTS OFFERED
    • TABLE 298 REGROW BIOSCIENCES PVT LTD.: PRODUCT APPROVALS, JANUARY 2021-MAY 2024
    • 12.1.14 TEGO SCIENCE, INC.
    • TABLE 299 TEGO SCIENCE, INC.: COMPANY OVERVIEW
    • TABLE 300 TEGO SCIENCE, INC.: PRODUCTS OFFERED
    • 12.1.15 CARSGEN THERAPEUTICS HOLDINGS LIMITED
    • TABLE 301 CARSGEN THERAPEUTICS HOLDINGS LIMITED: COMPANY OVERVIEW
    • TABLE 302 CARSGEN THERAPEUTICS HOLDINGS LIMITED: PRODUCTS OFFERED
    • TABLE 303 CARSGEN THERAPEUTICS HOLDINGS LIMITED: PRODUCT APPROVALS, JANUARY 2021-MAY 2024
    • TABLE 304 CARSGEN THERAPEUTICS HOLDINGS LIMITED: EXPANSIONS
    • TABLE 305 CARSGEN THERAPEUTICS HOLDINGS LIMITED: DEALS
    • 12.1.16 IASO BIOTHERAPEUTICS
    • TABLE 306 IASO BIOTHERAPEUTICS: COMPANY OVERVIEW
    • TABLE 307 IASO BIOTHERAPEUTICS: PRODUCTS OFFERED
    • TABLE 308 IASO BIOTHERAPEUTICS: PRODUCT APPROVALS
    • TABLE 309 IASO BIOTHERAPEUTICS: DEALS
    • 12.1.17 ANTEROGEN.CO.,LTD.
    • TABLE 310 ANTEROGEN.CO.,LTD.: COMPANY OVERVIEW
    • TABLE 311 ANTEROGEN.CO.,LTD.: PRODUCTS OFFERED
    • 12.1.18 GREEN CROSS HOLDINGS CO., LTD. (GC CELL)
    • TABLE 312 GREEN CROSS HOLDINGS CO., LTD. (GC CELL): COMPANY OVERVIEW
    • FIGURE 49 GREEN CROSS HOLDINGS CO., LTD. (GC CELL): COMPANY OVERVIEW (2023)
    • TABLE 313 GREEN CROSS HOLDINGS CO., LTD. (GC CELL): PRODUCTS OFFERED
    • TABLE 314 GREEN CROSS HOLDINGS CO., LTD. (GC CELL): DEALS
    • 12.1.19 SANPOWER GROUP CO., LTD. (DENDREON PHARMACEUTICALS LLC.)
    • TABLE 315 SANPOWER GROUP CO., LTD.: COMPANY OVERVIEW
    • TABLE 316 SANPOWER GROUP CO., LTD. (DENDREON): PRODUCTS OFFERED
  • 12.2 OTHER PLAYERS
    • 12.2.1 PROKIDNEY CORP.
    • TABLE 317 PROKIDNEY CORP.: COMPANY OVERVIEW
    • 12.2.2 BIOCARDIA, INC.
    • TABLE 318 BIOCARDIA, INC.: COMPANY OVERVIEW
    • 12.2.3 NEUROPLAST B.V.
    • TABLE 319 NEUROPLAST B.V.: COMPANY OVERVIEW
    • 12.2.4 ADAPTIMMUNE THERAPEUTICS PLC
    • TABLE 320 ADAPTIMMUNE THERAPEUTICS PLC.: COMPANY OVERVIEW
    • 12.2.5 AGONOX, INC.
    • TABLE 321 AGONIX, INC.: COMPANY OVERVIEW
    • 12.2.6 KYVERNA THERAPEUTICS, INC.
    • TABLE 322 KYVERNA THERAPEUTICS, INC.: COMPANY OVERVIEW
    • 12.2.7 OBSIDIAN THERAPEUTICS, INC.
    • TABLE 323 OBSIDIAN THERAPEUTICS, INC.: COMPANY OVERVIEW
    • 12.2.8 AVOTRES INC.
    • TABLE 324 AVOTRES, INC.: COMPANY OVERVIEW
    • 12.2.9 CORESTEMCHEMON INC.
    • TABLE 325 CORESTEMCHEMON INC.: COMPANY OVERVIEW
    • 12.2.10 JUVENTAS CELL THERAPY LTD.
    • TABLE 326 JUVENTAS CELL THERAPY LTD.: COMPANY OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS